Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme

We herein report for the first time the successful use of the Dipeptidyl Peptidase IV (DPPIV/CD26) prodrug approach to guanine derivatives such as the Antiviral acyclovir (ACV). The solution- and solid-phase synthesis of the tetrapeptide amide prodrug 3 and the tripeptide ester conjugate 4 of acyclovir are reported. The synthesis of the demanding tetrapeptide amide prodrug of ACV 3 was first established in solution and successfully transferred onto solid support by using Ellman's dihydropyran (DHP) resin. In contrast with the valyl ester prodrug (valacyclovir, VACV), the tetrapeptide amide prodrug 3 and the tripeptide ester conjugate 4 of ACV proved fully stable in PBS. Both prodrugs converted to VACV (for 4) or ACV (for 3) upon exposure to purified DPPIV/CD26 or human or bovine serum. Vildagliptin, a potent inhibitor of DPPIV/CD26 efficiently inhibited the DPPIV/CD26-catalysed hydrolysis reaction. Both amide and ester prodrugs of ACV showed pronounced anti-herpetic activity in Cell Culture and significantly improved the water solubility in comparison with the parent drug.

ACV; Acyclovir; Antiviral; DHP; DKP; DPP IV; Dipeptidyl peptidase IV; Peptide; Prodrug; Solid-phase synthesis; VACV; acyclovir; dihydropyran; diketopiperazine; dipeptidyl peptidase IV; valacyclovir.